HIV Clinical Trial
Official title:
GRACE: An Open-label, Multicenter Trial to Compare the Efficacy, Safety, and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race, When Administered in Combination With an Individually Optimized Background Regimen Over a 48-week Treatment Period.
The purpose of this study is to evaluate any differences in the effectiveness, safety, and tolerability of PREZISTA (darunavir; DRV) 600 mg, administered with ritonavir (RTV) 100 mg twice a day on virologic response (defined as a viral load (VL) of < 50 copies/mL) over a 48-week treatment period in HIV-positive women and men. Additional antiretroviral (ARV) agents will also be administered and will be chosen by the Investigator based on resistance testing and prior treatment history (referred to as the Optimized Background Regimen (OBR)).
This is a multi-center, open-label (doctors and patients know which drug is being
administered), Phase IIIb clinical trial to evaluate differences in effectiveness, safety,
and tolerability of darunavir/ritonavir by sex and/or race over a 48-week treatment period.
This study will be conducted in HIV positive women and men who have been treated previously
with antiretroviral therapy. This study will enroll 70% women and will be conducted in the
U.S., Puerto Rico, Mexico and Canada in approximately 420 patients who will receive
darunavir 600 mg and ritonavir 100 mg twice daily. The primary objective of this study is to
determine the percentage of patients who achieve virologic response, defined as a viral load
(VL) of <50 copies/mL at week 48. Secondary study objectives include comparisons of
endpoints between women and men as well as race across multiple parameters including but not
limited to change in CD4 count from baseline to week 48, time to loss of virologic response
(TLOVR), changes in metabolic parameters (blood chemistry), etc.
Within 4 weeks after the Screening Visit (initial visit with investigator to determine
eligibility), the Investigator should have received all data required to determine the
patient's eligibility and will construct the individual Optimized Background Regimen (OBR)
that will be used during the treatment period in combination with darunavir/ritonavir for
those patients enrolled in the study. The OBR will consist of additional antiretroviral
(ARV) agents that will also be administered during the study chosen by the Investigator and
based on resistance testing and prior treatment history. The study Sponsor will provide the
following ARV agents, that may be used as options for the OBR: TMC 125 (investigational
non-nucleoside reverse transcriptase inhibitor; NNRTI); Truvada (tenofovir/emtricitabine);
Viread (tenofovir); Emtriva (emtricitabine); Zidovudine. Other NRTIs (nucleoside reverse
transcriptase inhibitors) or NNRTIs may be used at the discretion of the Investigator, but
will not be provided by the Sponsor. The Baseline Visit (Day 1) will be followed by a
48-week treatment period during which patients will be evaluated at Weeks 4, 8, 12, 16, 24,
36, 48 and at a final Follow-Up Visit during Week 52. (total of 10 visits from Screening to
final visit). At a number of visits throughout the study, blood samples will be obtained to
assess defined laboratory values, safety parameters and to determine concentrations of study
drugs darunavir, TMC125 (if applicable) and ritonavir). Patients will be assessed for change
in CD4 count and HIV-RNA throughout the study. At each visit, vital signs will be assessed
and patients will be asked about any untoward medical occurrences and these will be recorded
as adverse events (AEs) and/or HIV-related events. Detailed definitions and reporting
procedures for AEs will be provided as part of the protocol. Study patients will receive
PREZISTA (darunavir) 600 mg boosted with 100 mg of ritonavir orally (by mouth) twice a day
in combination with other antiretroviral drugs for 48 weeks.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |